🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. BEVACIZUMAB, PEMBROLIZUMAB, VINORELBINE, GEMCITABINE, NIVOLUMAB, PEMETREXED, PACLITAXEL, CARBOPLATIN

    CERO THERAPEUTICS HOLDINGS, INC.

    Non Small Cell Lung Cancer, Interstitial Lung Disease

    phase 2 small molecule active

    1 trial

  2. BGB-A317

    The First People's Hospital of Lianyungang

    Gastric Cancer

    phase 2 small molecule completed

    1 trial

  3. BGB-A445

    BEONE MEDICINES AUS PTY LTD

    Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  4. BGJ398

    Novartis Pharmaceuticals

    Recurrent Glioblastoma or Other Glioma Subtypes

    phase 2 small molecule completed

    1 trial

  5. BGJ398 (infigratinib)

    BridgeBio Oncology Therapeutics

    Advanced Cholangiocarcinoma

    phase 2 small molecule terminated

    1 trial

  6. BI 3000202, BI 3000202, Placebo matching BI 3000202

    Boehringer Ingelheim

    Systemic lupus erythematosus

    phase 2 small molecule active

    1 trial

  7. BI 907828, Ezabenlimab, BI 907828, BI 907828

    The George Institute

    Adult patients with locally advanced/metastatic solid tumors

    phase 2 small molecule active

    1 trial

  8. BIIB122 225 mg

    Denali Therapeutics

    Parkinson Disease

    phase 2 small molecule active

    1 trial

  9. BIIB122, Placebo to BIIB122

    Denali Therapeutics

    Parkinson’s disease

    phase 2 small molecule active

    1 trial

  10. BLEOMYCIN, CISPLATIN

    Fondazione Telethon ETS

    patients with newly diagnosed or recurrent high-grade or initially invasive precancerous squamous lesions of the vulva and non-invasive vulvar Paget's disease

    phase 2 small molecule active

    1 trial

  11. BLEOPRIM 15 mg polvere per soluzione iniettabile, Fluorouracile Teva 250 mg/5 ml soluzione per infusione, CARBOPLATINO TEVA 10 mg/ml concentrato per soluzione per infusione, CETUXIMAB, PEMBROLIZUMAB, Cisplatino Teva Italia 0,5 mg/ml concentrato per soluzione per infusione

    Fondazione Telethon ETS

    CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX

    phase 2 small molecule active

    1 trial

  12. BM-MSCs

    The First People's Hospital of Lianyungang

    Kidney Transplantation

    phase 2 other active

    2 trials

  13. BMS-986165

    Bristol-Myers Squibb

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  14. BOOST cells

    The George Institute

    Osteogenesis Imperfecta (OI) type III and severe type IV. Severe type of congenital Brittle bone disease.

    phase 2 small molecule active

    1 trial

  15. BOTULINUM TOXIN , -

    The George Institute

    Myogenous temporomandibular disorders (TMDM)

    phase 2 small molecule active

    1 trial

  16. BRENSOCATIB, MOMETASONE , BRENSOCATIB, The placebo used the same excipients as that used in IMP without active drug substance. The placebo was developed as film-coated tablet same in size and appearance to the IMP.

    Insmed Limited

    Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

    phase 2 small molecule active

    1 trial

  17. BRIGATINIB, Alunbrig 180 mg film-coated tablets, Alunbrig 90 mg film-coated tablets, Alunbrig 30 mg film-coated tablets

    AXIM BIOTECHNOLOGIES, INC.

    Anaplastic Large Cell Lymphoma (ALCL), Inflammatory Myofibroblastic Tumors (IMT), Other solid tumors

    phase 2 small molecule active

    1 trial

  18. BT1718

    BICYCLE THERAPEUTICS

    Advanced Solid Tumours

    phase 2 small molecule completed

    1 trial

  19. BT8009, Zelenectide Pevedotin

    BICYCLE THERAPEUTICS

    NECTIN4 Amplified Advanced Breast Cancer

    phase 2 small molecule active

    1 trial

  20. BT8009, Zelenectide Pevedotin, PEMBROLIZUMAB

    BICYCLE THERAPEUTICS

    Nectin-4 Expressing Advanced Malignancies.

    phase 2 small molecule active

    1 trial

  21. BXCL501 Sublingual Film

    BioXcel Therapeutics

    Bipolar I Disorder

    phase 2 small molecule completed

    1 trial

  22. BXCL701

    BioXcel Therapeutics

    Metastatic Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  23. BXCL701 plus Pembrolizumab

    BioXcel Therapeutics

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  24. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources